Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Capitalization 17.26B 973M 841M 762M 731M 1.33B 89.32B 1.39B 9.01B 3.6B 42.8B 3.65B 3.57B 153B P/E ratio 2025
11.1x
P/E ratio 2026 * 8.09x
Enterprise value 22.01B 1.24B 1.07B 971M 933M 1.7B 114B 1.78B 11.49B 4.59B 54.58B 4.66B 4.56B 196B EV / Sales 2025
1x
EV / Sales 2026 * 1.2x
Free-Float
66.05%
Yield 2025 *
4.53%
Yield 2026 * 4.65%
1 day+0.23%
1 week-0.45%
Current month-3.07%
1 month+8.81%
3 months-4.28%
6 months-21.78%
Current year-1.23%
1 week 17.19
Extreme 17.19
18.22
1 month 16.56
Extreme 16.56
18.5
Current year 15.89
Extreme 15.89
18.5
1 year 15.89
Extreme 15.89
26.06
3 years 12.39
Extreme 12.39
29.18
5 years 12.39
Extreme 12.39
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 12/04/2023
Director of Finance/CFO - 01/12/2015
Human Resources Officer - 01/09/2007
Director TitleAgeSince
Chairman - 30/10/1996
Director/Board Member - 06/07/2010
Director/Board Member - -
Change 5d. change 1-year change 3-years change Capi.($)
+0.23%-0.45%-28.81%+17.10% 981M
-2.02%-3.79%+5.76%+208.78% 897B
-2.31%-1.58%+45.12%+55.58% 591B
-1.63%+3.41%+9.84%+48.89% 418B
-2.03%-3.33%+15.93%+28.35% 368B
-2.08%-2.22%+22.48%+37.00% 313B
-2.24%-2.56%+24.82%+57.30% 312B
-3.50%-2.71%+24.55%+8.60% 297B
-3.08%-3.09%+16.12%+56.55% 204B
-2.08%+0.95%+25.73%+79.03% 184B
Average -1.86%-1.49%+16.15%+59.72% 358.47B
Weighted average by Cap. -1.96%-1.52%+20.05%+86.21%

Financials

2025 2026 *
Net sales 17.81B 1B 868M 786M 755M 1.38B 92.17B 1.44B 9.3B 3.72B 44.16B 3.77B 3.69B 158B 18.02B 1.02B 878M 795M 764M 1.39B 93.26B 1.45B 9.41B 3.76B 44.68B 3.81B 3.73B 160B
Net income 1.7B 95.63M 82.7M 74.89M 71.9M 131M 8.78B 137M 886M 354M 4.21B 359M 351M 15.09B 1.97B 111M 95.82M 86.77M 83.3M 152M 10.18B 159M 1.03B 410M 4.88B 416M 407M 17.48B
Net Debt 4.75B 268M 232M 210M 201M 367M 24.6B 383M 2.48B 992M 11.78B 1.01B 984M 42.26B 4.45B 251M 217M 197M 189M 344M 23.05B 359M 2.33B 929M 11.04B 942M 922M 39.59B
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,708
Date Price Change Volume
05/03/26 17.67 $ +0.23% 7,064,617
04/03/26 17.63 $ +0.80% 4,296,246
03/03/26 17.49 $ -1.30% 5,092,384
02/03/26 17.72 $ -2.80% 4,385,300
27/02/26 18.23 $ +2.70% 4,381,835
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.67MXN
Average target price
26.20MXN
Spread / Average Target
+48.27%

Quarterly revenue - Rate of surprise